TITLE

The Expression of the Thrombin Receptors PAR-3 and PAR-4 is Downregulated in Pancreatic Cancer Cell Lines

AUTHOR(S)
Rudroff, Claudia; Richard, Annette; Hilswicht, Sarah; Neugebauer, Edmund A. M.
PUB. DATE
January 2014
SOURCE
Jurnalul de Chirurgie;2014, Vol. 10 Issue 1, p31
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Patients with pancreatic cancer frequently suffer from thrombosis as a consequence of excess thrombin generation. In addition to its role in the plasmatic coagulation cascade, thrombin induces numerous cellular effects by activating a unique group of G-protein-coupled receptors on the cell membrane, the proteinase-activated receptors (PARs). At present, PAR-1, PAR-3 and PAR-4 are known to be activated by thrombin. We previously demonstrated a putative role for PAR-1 in pancreatic cancer progression, but little is known about the physiological and pathophysiological roles of PAR-3 and PAR-4. In the present study, we examined the expression patterns of PAR-3 and PAR-4 in pancreatic tissue and pancreatic cancer cells. Methods: Tissue samples from three patients with pancreatic adenocarcinoma and six human pancreatic carcinoma cell lines were examined. Gene expression was analysed by RT-PCR and quantified by HPLC. Protein expression was determined by Western blot analysis. Data analysis was performed using ANOVA in SPSS. Results and Conclusion: In contrast to PAR-1, both PAR-3 and PAR-4 were expressed in healthy pancreases but downregulated in pancreatic cancer. The contrasting expression patterns of PAR-3 and PAR-4 compared with PAR-1 indicate that the mechanism that regulates the cellular effects of thrombin on tumor progression remains to be fully elucidated.
ACCESSION #
97323040

 

Related Articles

  • P618 PAR2 expression differentially regulates immune response upon treatment with Poly(I:C) and LPS. Weithaeuser, A; Schultheiss, HP; Rauch, U // Cardiovascular Research;Jul2014, Vol. 103 Issue suppl_1, pS112 

    Introduction: The protease activated receptor 2 (PAR2) is a G-protein coupled receptor, that is activated by serine proteases such as trypsin, tryptase and the complex composed of tissue factor (TF)/ factor VII (FVII) and factor X (FX). PAR2 is also involved in modulating immune response after...

  • Increased Expression of Protease-Activated Receptor 4 and Trefoil Factor 2 in Human Colorectal Cancer. Yu, Guoyu; Jiang, Ping; Xiang, Yang; Zhang, Yong; Zhu, Zhu; Zhang, Chuanrao; Lee, Siman; Lee, Wenhui; Zhang, Yun // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Protease-activated receptor 4 (PAR4), a member of G-protein coupled receptors family, was recently reported to exhibit decreased expression in gastric cancer and esophageal squamous cancer, yet increased expression during the progression of prostate cancer. Trefoil factor 2 (TFF2), a small...

  • Altered Protease–Activated Receptor-1 Expression and Signaling in a Malignant Pleural Mesothelioma Cell Line, NCI-H28, with Homozygous Deletion of the β-Catenin Gene. Fazzini, Alessandra; D’Antongiovanni, Vanessa; Giusti, Laura; Da Valle, Ylenia; Ciregia, Federica; Piano, Ilaria; Caputo, Antonella; D’Ursi, Anna Maria; Gargini, Claudia; Lucacchini, Antonio; Mazzoni, Maria Rosa // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    Protease activated receptors (PARs) are G-protein coupled receptors that are activated by an unique proteolytic mechanism. These receptors play crucial roles in hemostasis and thrombosis but also in inflammation and vascular development. PARs have also been implicated in tumor progression,...

  • Down-regulation of PAR1 activity with a pHLIP-based allosteric antagonist induces cancer cell death. Burns, Kelly E.; Thèvenin, Damien // Biochemical Journal;12/15/2015, Vol. 472 Issue 3, p287 

    Even though abnormal expression of G protein-coupled receptors (GPCRs) and of their ligands is observed in many cancer cells of various origins, only a few anti-cancer compounds directly act on their signalling. One promising approach to modulate their activity consists of targeting the receptor...

  • PERSPECTIVE. Coughlin, Shaun // Cardiology Today;Jun2014, Vol. 17 Issue 6, p30 

    The author discusses the health benefits of protease activated receptor-1 (PAR-1).

  • GPER functions as a tumor suppressor in triple-negative breast cancer cells. Weißenborn, Christine; Ignatov, Tanja; Ochel, Hans-Joachim; Costa, Serban; Zenclussen, Ana; Ignatova, Zoya; Ignatov, Atanas // Journal of Cancer Research & Clinical Oncology;May2014, Vol. 140 Issue 5, p713 

    Background: The orphan, membrane-bound estrogen receptor (GPER) is expressed at high levels in a large fraction of breast cancer patients and its expression is favorable for patients' survival. Methods: We investigated the role of GPER as a potential tumor suppressor in triple-negative breast...

  • Data from TRACER Study of Vorapaxar, Merck's Investigational Medicine for Cardiovascular Disease, Presented at AHA and Published in NEJM.  // Biomedical Market Newsletter;11/14/2011, Vol. 21, p282 

    The article presents the results of the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) study led by North Carolina's Duke Clinical Research Institute (DCRI). The study is the first clinical trial of vorapaxar from Merck & Co. Inc. for the prevention...

  • Insulin-like growth factor-I regulates GPER expression and function in cancer cells. De Marco, P; Bartella, V; Vivacqua, A; Lappano, R; Santolla, M F; Morcavallo, A; Pezzi, V; Belfiore, A; Maggiolini, M // Oncogene;2/7/2013, Vol. 32 Issue 6, p678 

    Functional cross talk between insulin-like growth factor-I (IGF-I) system and estrogen signaling has been largely reported, although the underlying molecular mechanisms remain to be fully elucidated. As GPR30/GPER mediates rapid cell responses to estrogens, we evaluated the potential of IGF-I to...

  • GIT1 is a novel prognostic biomarker and facilitates tumor progression via activating ERK/ MMP9 signaling in hepatocellular carcinoma. Junyi Chen; Pinghua Yang; Jue Yang; Zhijian Wen; Baohua Zhang; Xin Zheng // OncoTargets & Therapy;Dec2015, Vol. 8, p3731 

    Aim: Multiple studies have revealed that G-protein-coupled receptor kinase-interacting protein 1 (GIT1) is overexpressed in many cancers and facilitates tumor progression. However, the role of GIT1 in hepatocellular carcinoma (HCC) remains unclear. Methods: GIT1 expression was detected in cell...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics